Sign in
Active, not recruitingNo phase

The Applanation Tonometry in GCA Pilot

Key facts

Who runs it
Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
Where
Canada1 site in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
People taking part
146 people, planned
Started
30 Jul 2025
Expected to end
Jul 2027
Type of study
Observational, 2 groups
Treatments tested
  • Applanation tonometry
  • Standardized GCA assessment
  • Repeat applanation tonometry (optional)
Record updated
21 October 2026

Who can take part

Age
50 years to 99 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • To be included in ATOM-GCA, participants must meet all the following criteria:
  • Age > 50 years
  • Referral for suspected, new-onset GCA
  • Ability to understand and willingness to sign an informed consent form
  • Willingness to comply with study visits and procedures

Who cannot take part

  • Current use of systemic glucocorticoids, with the following duration at the baseline visit:; ≥ 14 consecutive days of oral glucocorticoids in the previous 30 days, or; ≥ 7 consecutive days of oral glucocorticoids if intravenous glucocorticoids were administered in the previous 30 days
  • Current use of any conventional or biologic immunosuppressive therapy
  • Temporal artery biopsy prior to the study visit
  • An individual who meets any of these criteria will be excluded from ATOM-GCA:
  • Referral for a suspected GCA relapse

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The Applanation Tonometry in Giant Cell Arteritis (ATOM-GCA) study will answer the following questions:

Read full original descriptionShow less

1. How does PWV, measured by applanation tonometry of temporal arteries, differ between patients with and without a final diagnosis of GCA (based on pre-defined criteria 6 months after inclusion)? 2. What is the diagnostic accuracy and positivity cutoff of the PWV, measured by applanation tonometry, in detecting:

1. A clinical diagnosis of GCA (based on pre-defined criteria 6 months after inclusion)? 2. Inflammation of temporal arteries on high-resolution ultrasound? 3. What is the acceptability and adherence of repeat applanation tonometry during the follow-up period in patients with GCA?

The 2 groups in the trial

  • GCA group

    Definite confirmation of GCA will occur 6 months after study inclusion, following the phone follow-up, and will require all the following features: 1) initial symptoms and clinical evolution consistent with GCA; 2) at least one positive test for cranial GCA (ultrasound of temporal arteries, temporal artery biopsy, cranial MRI, cranial PET); and 3) satisfies the 2022 ACR-EULAR classification criteria for GCA.

    Treatment: Applanation tonometry, Standardized GCA assessment, and Repeat applanation tonometry (optional)

  • Non-GCA group

    Participants who do not meet the criteria (above) for GCA at month 6.

    Treatment: Applanation tonometry and Standardized GCA assessment

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Applanation Tonometry in Giant Cell Arteritis Pilot
Record updated
21 October 2026